ArticleAdvances in therapy2026
Lateral Femoral Cutaneous Nerve Radiofrequency Ablation for the Treatment of Meralgia Paresthetica: A Retrospective Case Series.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMeralgia paresthetica is a chronic pain condition that is becoming more common due to increases in obesity and diabetes across the general population. This condition results from damage to or dysfunction of the lateral femoral cutaneous nerve (LFCN). Sensory dysfunction without motor impairment is a hallmark of meralgia paresthetica due to the LFCN being a sensory-only nerve. Symptoms affect the anterolateral to lateral thigh and include pain, tingling, burning, and numbness. Current management options include weight loss, loose clothing, physical therapy, oral medications, corticosteroid injections, and surgery. Radiofrequency ablation (RFA) may be a minimally invasive treatment option used before surgery. Although RFA has demonstrated efficacy for other nerve targets, there is currently insufficient evidence for LFCN RFA. The objective of this retrospective study was to add to the existing evidence by examining the safety and efficacy of thermal LFCN RFA for the treatment of meralgia paresthetica during a short-term follow-up of < 2 months.
methodsThis was a single-site retrospective case series that obtained data from electronic medical records of all patients who underwent thermal LFCN RFA between 2014 and 2025. Other RFA types (cooled and pulsed) were excluded. The 10-cm visual analog scale (VAS) was used to assess pain at baseline and post-procedurally. Statistical analysis was performed using a paired t test in SPSS version 30.
resultsThirteen cases involving eight patients were included in this analysis, three of whom underwent the procedure multiple times. VAS scores decreased from 5.77 ± 1.92 to 3.23 ± 2.09 (p = 0.007) after the procedure. A reduction in pain was noted in 9/13 cases. For patients with a reduction in pain, the mean improvement was 62.04%, and pain relief was sustained for 6.43 ± 4.65 months. There were no instances of adverse events.
conclusionOur study found thermal LFCN RFA to be safe and effective for a high proportion of patients with meralgia paresthetica who have exhausted conservative management options. Future studies should include prospective data, additional parameters, larger sample sizes, and long-term fixed follow-ups.
Indexed as
Identifiers
42821229What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.